NCT02218073View on ClinicalTrials.gov

Pharmacokinetic Study of JNJ-42756493 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Healthy
Interventions
DRUG

JNJ-42756493 10 mg tablet

Participants will be administered with 10 milligram (mg) JNJ-42756493 tablet orally either on Day 1 of Period 1 or on Day 1 of Period 2.

DRUG

JNJ-42756493 10 mg Oral Solution

Participants will be administered with 10 mg JNJ-42756493 oral solution either on Day 1 of Period 1 or on Day 1 of Period 2.

DRUG

JNJ-61818549

Participants will receive 100 mcg of JNJ-61818549 as intravenous injection on Day 1 of Period 2 or Day 1 of Period 1.

Trial Locations (1)

Unknown

Merksem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02218073 - Pharmacokinetic Study of JNJ-42756493 in Healthy Participants | Biotech Hunter | Biotech Hunter